Mind Medicine Inc - Ordinary Shares (Sub Voting) Stock News

NEW YORK--(BUSINESS WIRE)--Mind Medicine (MindMed) Inc. (NASDAQ: MNMD), (the "Company" or "MindMed"), a late-stage clinical biopharmaceutical company developing novel product candidates to treat brain health disorders, today announced that JAMA has published full results from the Company's positive Phase 2b study of MM120 (lysergide D-tartrate, LSD) in 198 adults with moderate-to-severe GAD. Th...

NEW YORK--(BUSINESS WIRE)--Mind Medicine (MindMed) Inc. (NASDAQ: MNMD) (the “Company” or “MindMed”), a late-stage clinical biopharmaceutical company developing novel product candidates to treat brain health disorders, today announced that members of the Company's management team will participate in the following investor conferences: Cantor Global Healthcare Conference 2025 Format: Fireside Cha...

Mind Medicine (MNMD 1.32%) is a clinical stage biotech company that's aiming to bring psychedelics and other compounds to market as forms of treatments for conditions including generalized anxiety disorder (GAD), major depressive disorder (MDD), and autism spectrum disorder (ASD). The business is still in a pre-revenue state and has a highly uncertain forward performance trajectory, but it's re...

NEW YORK--(BUSINESS WIRE)--Mind Medicine (MindMed) Inc. (NASDAQ: MNMD) (the “Company” or “MindMed”), a late-stage clinical biopharmaceutical company developing novel product candidates to treat brain health disorders, today announced the issuance of inducement grants to five newly hired non-executive employees consisting of (i) options to purchase an aggregate of 425,450 common shares of the Co...

By their nature, clinical-stage biotech companies can be volatile investments. Even by that standard, MindMed (MNMD 2.59%) is quite a risky play; after all, a key element of its business strategy is to develop brain health medications based on compounds that are illegal on the federal level in the U.S.

Mind Medicine (MindMed) (MNMD -7.26%), a biopharmaceutical company developing psychedelic-inspired therapies for brain health disorders, reported its second quarter results on July 31, 2025. The company recorded a GAAP EPS loss of $0.50, wider than analyst expectations of $0.38.

Mind Medicine (MindMed) Inc. (NASDAQ:MNMD ) Q2 2025 Earnings Conference Call July 31, 2025 4:30 PM ET Company Participants Brandi L. Roberts - Chief Financial Officer Daniel Rollings Karlin - Chief Medical Officer Matthew Wiley - Chief Commercial Officer Robert Barrow - CEO & Director Stephanie Fagan - Chief Corporate Affairs Officer Conference Call Participants Brian Corey Abrahams - RBC Capit...

NEW YORK--(BUSINESS WIRE)--Mind Medicine (MindMed) Inc. (NASDAQ: MNMD), (the "Company" or "MindMed"), a late-stage clinical biopharmaceutical company developing novel product candidates to treat brain health disorders, today announced its second quarter 2025 financial results and provided an update on business highlights. “We continue making significant progress across all three of our pivotal ...